Comparative Pharmacology
Head-to-head clinical analysis: ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL versus FEMRING.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL versus FEMRING.
ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL vs FEMRING
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination hormonal contraceptive: ethynodiol diacetate is a progestin that suppresses gonadotropin secretion (LH and FSH) via negative feedback on the hypothalamic-pituitary axis, inhibiting ovulation; ethinyl estradiol is an estrogen that stabilizes the endometrium and increases cervical mucus viscosity, impeding sperm penetration.
Femring (estradiol acetate) is a vaginal ring that releases estradiol, which binds to estrogen receptors (ERα and ERβ) in target tissues, regulating gene transcription and exerting estrogenic effects on the vaginal epithelium, urogenital tract, and other estrogen-sensitive tissues.
1 tablet (1 mg ethynodiol diacetate / 35 mcg ethinyl estradiol) orally once daily for 21 days, followed by 7 placebo days.
Insert one vaginal ring containing 0.05 mg or 0.10 mg estradiol acetate per day; replace every 3 months.
None Documented
None Documented
Ethynodiol diacetate: 12-14 hours; ethinyl estradiol: 13-27 hours (mean ~17 hours). Steady-state achieved after 3-4 days.
The terminal elimination half-life of estradiol from the vaginal ring (Femring) is approximately 36 hours. This extended half-life supports once-monthly dosing and maintains steady-state concentrations.
Renal (approximately 40% as metabolites), fecal (approximately 60% as metabolites). Ethynodiol diacetate is extensively metabolized; less than 1% excreted unchanged.
Estradiol is primarily excreted in urine (about 90-95%) as conjugated metabolites (glucuronides and sulfates), with approximately 5-10% eliminated in feces via bile. Less than 5% is excreted unchanged.
Category D/X
Category C
Estrogen
Estrogen